thalidomide has been researched along with Leprosy, Macular in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment." | 5.08 | IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. ( Estrada-Garcia, I; Estrada-Parra, S; Favila-Castillo, L; Gomez-Melgar, M; Partida-Sanchez, S; Pedraza-Sanchez, S; Saul, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Velázquez de Castro y Sagarra, A | 1 |
| López Bueno, R | 1 |
| Gómez Jiménez, G | 1 |
| Partida-Sanchez, S | 1 |
| Favila-Castillo, L | 1 |
| Pedraza-Sanchez, S | 1 |
| Gomez-Melgar, M | 1 |
| Saul, A | 1 |
| Estrada-Parra, S | 1 |
| Estrada-Garcia, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909] | Phase 4 | 10 participants (Actual) | Interventional | 2019-09-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Leprosy, Macular
| Article | Year |
|---|---|
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Data Interpretation, Statistical; Erythema Nodosum; | 1998 |
1 other study available for thalidomide and Leprosy, Macular
| Article | Year |
|---|---|
[Suspected leprosy].
Topics: Adult; Aged; Aged, 80 and over; Dapsone; Diagnosis, Differential; Female; Humans; Leprostatic Agents | 1997 |